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Summary. Fibrinolysis appears in many diverse physiolog-
ical situations, and the components of the system are well
established, along with mechanistic details for the individ-
ual reactions and some high-resolution structures. Key
questions in understanding the regulation of fibrinolysis
surround mechanisms of initiation and propagation, the
localization of fibrinolysis reactions to the fibrin clot, and
the influence of fibrin structure and clot composition on
thrombolysis. This review covers these key areas with a
focus on recent developments on fibrin structure and
binding, the effects of a variety of cell types, the conse-
quences of histones and DNA released by neutrophils,
and the influence of flow. A complete understanding of
the regulation of fibrinolysis will come from the building
of detailed mathematical models. Suitable models are at
an early stage of development, but may improve as model
clots increase in complexity to incorporate the compo-
nents and interactions listed above.
Keywords: fibrin; fibrinolysis; plasminogen; thrombolytic
therapy.
Introduction
Fibrin is a substrate in fibrinolysis in two senses of the
word, being both a surface for the binding and develop-
ment of key reactions, and also a substance that an
enzyme, plasmin, acts upon. These two features may also
be viewed as delineating the two key steps of fibrinolysis
which are the generation of plasmin followed by the
digestion of fibrin. It is likely that the main players in the
fibrinolysis pathways have been identified, and individual
reactions have been extensively studied. The regulation of
fibrinolysis involves different mechanisms, including pro-
tease action, serpin inactivation and conformational
changes. Fibrin fiber diameter and clot architecture influ-
ence fibrinolysis, so clot stability and resistance is prede-
termined to a significant degree at the clot formation
stage. This brief review covers selected aspects of fibrino-
lysis with a focus on recent developments that improve
our understanding of regulation. Space does not allow for
many important historic citations which are replaced by
reference to more recent reviews and apologies are given
to original authors.
Fibrin binding and the initiation of fibrinolysis
Tissue plasminogen activator (tPA) is probably the most
widely studied plasminogen activator, as well as being
extensively used clinically as a therapeutic thrombolytic
(Alteplase), so much detail is available on its mechanism
of action. Key in understanding the regulation of tPA
activity is its colocalization with plasminogen on a fibrin
surface [1] (elaborated in Fig. 1), leading to stimulation in
activity of 102- to 103-fold, probably as a random-order
process [2]. Early investigations identified the main fibrin
binding sites, which are located primarily in the finger
domain and kringle 2 of tPA [3], and one or more of the
five kringle domains in plasminogen (see below). Kringle
domains often (though not always) contain lysine binding
sites (LBS) that bind to internal and C-terminal lysine
residues. C-terminal lysine residues generated by plasmin
are particularly important as a positive feedback mecha-
nism for the stimulation of fibrinolysis.
Fibrin binding sites
A molecule of fibrinogen is a dimer where each subunit is
composed of three polypeptide chains forming distinct
structural regions, crucially a central E domain, com-
posed of N-terminal regions from each half of the dimer
and two symmetric distal D-domains (for a review of
fibrinogen structure, see [4] and Fig. 1A). Each fibrinogen
chain contains 104 lysine residues, but intact fibrin ini-
tially has no C-terminal lysines. This initial fibrin struc-
ture demonstrates only a weak affinity for the native full
length form of plasminogen (Glu-plasminogen), with Kd
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values in the 105 M range, higher than the plasma
concentration of plasminogen (around 2 lM) [1,5]. How-
ever, published Kd values for the binding of plasminogen
and tPA molecules to fibrin are highly variable (e.g.
reviewed [6]).
Models for the initiation and propagation of fibrinoly-
sis have been developed, built upon binding and kinetic
studies using fibrinogen and fibrin fragments, synthetic
peptides, X-ray structure data, monoclonal antibodies
and natural variants of fibrinogen [4,7], and are summa-
rized in Fig. 1. Work with fibrinogen peptides drew atten-
tion to the sequences Aa148-160 (as a kringle-dependent
binding site, most likely for plasminogen) and c312-





































Fig. 1. Proposed scheme for initiation and propagation of fibrinolysis. Panel (A) shows the formation of fibrin highlighting the central (E-)
domain (green) of fibrinogen with the N-terminal fibrinopeptides A and B (red) that are cleaved from the Aa- and Bb-chains by thrombin
when fibrinogen is converted to fibrin. The distal (D-) domains (purple), composed of the C-terminal portions of the Bb- and c-chains, interact
with the E- and D-domains of adjacent fibrin monomers to form double-stranded protofibrils. The aC-domains (yellow) meet in the central
part of the fibrinogen molecule, initially connecting non-covalently in fibrin to form an extensive 3D network. At a later stage, FXIIIa forms
isopeptide bonds between c- and a-chains in adjacent monomers. The location of potential initial binding sites for plasminogen (stars) and tPA
(triangles) is indicated. Also shown are models of Glu-plasminogen and tPA indicating intramolecular bonding of domains, adapted from
[15,16] and [61], respectively. Panel (B) shows reaction sequences occurring during fibrinolysis as a template mechanism where a ternary com-
plex of fibrin-tPA-plasminogen (F-tPA-Pgn) forms to stimulate the generation of plasmin. The series of reactions in C shows the change from
fibrinogen (with weak, kringle-dependent binding sites [62,63]) to fibrin and subsequent series of fibrin degradation products (F, F0, F″, etc.).
Early events in fibrin formation include exposure of cryptic binding sites, indicated in panel (A). Plasmin generates C-terminal lysines providing
a positive feedback mechanism through enhanced plasminogen binding. Fibrin degradation leads to aggregate formation to focus the binding
of tPA (via finger domain) and plasminogen (at C-terminal lysines) around amyloid-like cross-b structures to complete fibrinolysis through a
series of fibrin degradation products, culminating in DDE the smallest FDP to bind tPA and plasminogen.
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Recombinant aC domain, Aa221-610, was also found to
include lysine dependent but distinct binding sites for
both tPA and plasminogen. Binding sites were localized
to the C-terminal portion from residue 392 and demon-
strated a high affinity for tPA and plasminogen (Kd 16–
33 nM), but this region in fibrin is cleaved early by plas-
min. However, this picture is complicated by other find-
ings that show a high dependence of tPA binding to C-
terminal lysines in fibrin degradation product, DDE
domain complexes. There are 8 C-terminal lysines, and
removal of four could drastically reduce the stimulation
of plasminogen activation by tPA [8]. A precise, simple
picture of the unmasking of specific binding sites during
fibrin formation is further challenged by longstanding
observations that tPA and plasminogen bind to many
denatured, aggregated or modified proteins [9]. tPA bind-
ing and plasminogen activation via this mechanism has
been termed the cross-b structure pathway [10]. Accord-
ing to this mechanism, stacked b-sheets (cross-b structures
with amyloid properties) bind to tPA finger domain resi-
dues with a particular alternating charge sequence, Arg7,
Glu9, Arg23, Glu32, Arg30, while plasminogen binding
and activation relies on C-terminal lysines. These observa-
tions bring into focus binding to fibrin fibrils or aggre-
gates. For example, addition of tPA to preformed clots
resulted in concentration of tPA to a narrow lytic zone
and the development of fibrin ‘agglomerates’ that tightly
bind plasminogen and tPA [11,12]. More recently, confo-
cal microscopy studies have shown green fluorescent pro-
tein fusions of tPA (tPA-GFP) bind fibrin aggregates [13],
primarily through the finger domain. Fingerless tPA-GFP
(ΔF tPA-GFP) interacts more weakly with aggregates,
results that agree with kinetic studies where it was esti-
mated that finger interactions account for 80% of the
binding of tPA to fibrin [14]. It was also observed that
aggregates form preferentially in fibrin composed of thick
fibers, not fine fibers, and stain with thioflavin T, a well-
known marker for cross-b structures (see Fig. 2).
Together, these results suggest a mechanistic link between
binding to fibrin and other protein aggregates, and high-
light differences in fibrinolysis between thin and thick
fibrin fibers (see below). Thus, some of the later fibrin
structures shown in Fig. 1C (F″ etc.), are aggregates that
concentrate tPA and plasminogen, at least in fibrin com-
posed of thick fibers (common in plasma clots [11]). The
variety of modes of interaction with fibrin and different
fibrin structures involved may explain the difficulties in
providing consistent estimates of Kd values for tPA and
plasminogen binding [6].
Plasminogen binding
Significant progress has been made recently from the
structural analysis of full length plasminogen (Glu-plas-
minogen, Glu1-Asn791) [15,16]. These structures shed
light on long-established observations, such as the role of
Cl ions in maintaining the closed conformation; the
affinity of different kringles for lysine analogues; and the
role of different kringles in triggering conformational
changes. In particular, the structures help explain the
resistance of Glu-plasminogen to activation and how
fibrin binding promotes activation to plasmin. Thus, a
key feature of control of plasminogen activation is termed
‘conformational regulation’ due to the relatively inert
closed spiral structure of Glu-plasminogen in which the
activation cleavage site at Arg561 is inaccessible to
plasminogen activators (as is a pro-activation site at






Fig. 2. Fibrin aggregate formation and characterization. Panel (A) shows fibrin aggregates from a scanning electron microscopy image follow-
ing 10 min of fibrinolysis after tPA was added to the surface of a preformed, coarse fiber clot made with 5 nM thrombin. Panel (B) shows a
similar clot made with orange labeled fibrinogen treated with tPA fused to jellyfish green fluorescent protein (tPA-GFP). Fibrin aggregates are
red spots and when merged with the green tPA-GFP image appear yellow, illustrating the strong association of fibrin aggregates and tPA. The
arrows indicate positions of the lysis front in two overlaid images showing the diffuse surface accumulation of tPA at 5 min and the appear-
ance of aggregates after 35 min at the new lysis front. Panel C shows the staining of fibrin aggregates by thioflavin T (ThT) after 45 min of
fibrinolysis with native (unlabeled) tPA. ThT fluorescence indicates the presence of amyloid-like cross-b structures, which are able to bind the
finger domain of tPA (images adapted from [13]).
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N-terminal peptide (NTP), kringles 1–5 and serine prote-
ase domain, and interdomain bonds particularly between
Lys50, Arg 69 and Arg70 of the NTP with kringles 4 and
5 that help maintain the closed structure (see Fig. 1A). If
the NTP is cleaved at Lys77 by plasmin (generating Lys-
plasminogen, Lys78-Asn791), the structure unfolds to
become more linear and Arg561 is accessible to plasmino-
gen activators. Lys77 is hidden in Glu-plasminogen but
may become available following a sequence of conforma-
tional changes. It is proposed that kringle 1 initially binds
fibrin and triggers undocking of kringles 4 and 5 from the
NTP to expose Lys77 and Arg561. However, other inter-
esting aspects of the activation pathway may involve dif-
ferences between plasminogen glycoforms and kringle 3,
which has no LBS. Glycoform I of plasminogen has two
carbohydrate moieties, one at Asn289 (on kringle 3)
which may destabilize the Glu-plasminogen closed confor-
mation and enable kringle 3 to be mobile. Furthermore,
two different conformations were found in the crystal
structure of glycoform II, and one was partially open
such that kringle 5 was available for lysine binding [15].
This is particularly interesting considering kringle 5 has a
preference for internal lysines, which could be relevant to
the initiation of fibrinolysis, before the generation of sig-
nificant plasmin that could produce C-terminal lysines in
fibrin.
Other activators
tPA is not the only plasminogen activator and it is impor-
tant to appreciate the variety of mechanisms that exist to
generate plasmin. Single chain urokinase plasminogen
activator (scuPA) is a zymogen precursor of active 2 chain
urokinase (uPA) and although scuPA/uPA is mostly
linked to cell-associated fibrinolysis (in association with a
specific receptor uPAR or CD87), studies with knockout
mice suggest a role in intravascular fibrinolysis [17]. scuPA
activity is fibrin-specific to some extent, possibly by a
number of mechanisms, although uPA has no direct affin-
ity for fibrin [18]. uPA activates plasminogen in solution,
so does not rely on a colocalization mechanism like tPA,
and uPA is more sensitive to the open conformation of
plasminogen [14]. Thus, while ‘antifibrinolytics’ such as
tranexamic acid or aminohexanoic acid block plasminogen
binding to fibrin and inhibit tPA activity, they bind to
kringle LBS to open up the inert conformation of Glu-
plasminogen and enhance activation by uPA, but not tPA
[14]. This conformational rather than colocalization mech-
anism is confirmed by studies on ‘fibrinolytic cross talk’
which describe scuPA or uPA bound to cells or microvesi-
cles activating plasminogen (in an appropriate open con-
formation) bound to a different surface [19].
Bacteria have adopted a number of strategies to pro-
mote invasion that involve hijacking the host plasminogen
system. Streptokinase (SK) is a first-generation thrombo-
lytic and the therapeutic molecule, which is isolated from
Streptococcus equisimilus, a Lancefield Group C strain, is
the most widely studied. However, other SK variants have
distinct mechanisms that rely on interactions with bacte-
rial cell surface proteins such as PAM and M1, which
bind plasminogen and fibrinogen, respectively [20]. Other
bacterial proteins, including another binding protein,
staphylokinase from Staphylococcus and the pla enzyme
from Yersinia pestis, have been extensively studied, and
much information regarding mechanism of action, struc-
tural–function relationships, is available [15,16,21].
Inhibition of fibrinolysis
Mechanisms are needed to reduce unwanted systemic
plasmin generation to avoid excessive degradation of
plasma proteins. Inert conformations of plasminogen and
fibrinogen represent an important barrier to plasminogen
activation, bearing in mind single chain tPA is an active
enzyme, not a zymogen [22]. The two most critical serpin
inhibitors in fibrinolysis are plasminogen activator
inhibitor 1 (PAI-1) and alpha-2 plasmin inhibitor (a2PI,
or a2-antiplasmin). Both these inhibitors circulate at
concentrations in the same range as their potential
enzyme targets and both are very potent with second-
order rate constants for inhibited complex formation
around 107 M1 s1, close to the diffusion controlled
limit. However, plasmin bound to fibrin, or lysine ana-
logues, is inhibited much more slowly by a2PI, allowing
time for plasmin to act where needed, and most protec-
tion appears with the formation of C-terminal lysines [23].
PAI-1 inhibits both uPA and tPA and the rate constants
quoted are also high, but these values refer to free solu-
tion and are also modulated by fibrin and fibrinogen [22].
Other serpins may form complexes with plasmin, tPA or
uPA, including PAI-2 and PAI-3 and protease nexin; and
a2-macroglobulin also forms a further back up.
Within a clot, fibrinolysis may be inhibited by a metal-
loproteinase, thrombin-activatable fibrinolysis inhibitor
(TAFIa) or carboxypeptidase U (CPU) [24,25]. This pro-
tein circulates in an inactive zymogen form (TAFI or
pro-CPU) and is activated by thrombin/thrombomodulin
or plasmin during on-going fibrinolysis. Once activated,
the enzyme cleaves C-terminal lysines in fibrin, critical for
the binding of plasminogen as discussed above, and
mechanistic studies have identified a threshold behavior
and the involvement of other plasma inhibitors, including
a2PI. Several approaches suggest TAFIa acts predomi-
nantly by reducing binding of plasminogen or plasmin,
rather than through lysine binding of tPA via kringle 2
[14,23,26]. The crystal structure of TAFI has been solved
and provides a rationale for the known thermal instability
of the protein at 37 °C, which forms an important regula-
tory mechanism [27,28]. Both PAI-1 and TAFI, being
associated with adverse cardiovascular events or cancer
(in the case of PAI-1), have been targets for drug devel-
opment [25].
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Plasmin digestion of fibrin
The degradation of fibrin by plasmin is not well under-
stood, probably accounted for in part by the difficulties
of studying enzymology at a solid–liquid interface. As
mentioned above, the aC-domains in fibrin are an early
target for plasmin (cleavage of at least 10 bonds next to
lysine or arginine residues results in a highly heteroge-
neous set of early degradation products [29]) followed by
removal of a peptide from the N-terminal of the b-chain
(cleaved primarily at Arg42 [30]) and cleavage of the
coiled coil connector of the E- and D-domains [31]
(at aLys81-bLys122-cLys59 or aArg104-bLys133-cLys63
[32]). Several lines of evidence suggest that efficient solu-
bilization of the fibrin meshwork requires only 25% of
the total E–D connections need to be broken and 50%
of the fibrin monomers can remain intact [33]. However,
all three polypeptide chains of the triple helical structure
within a fibrin monomer must be cleaved through the
same cross section in both adjacent monomers within a
protofibril and in all adjacent protofibrils within a fiber.
The cited low fraction of E–D connections broken at dis-
solution suggests that cleavage of fibrin fibers is achieved
by clustering of plasmin molecules at points on a fiber
rather than uniformly along the fiber, and evidence for
preferential transversal cleavage of the fibers is provided
by atomic force microscopic images of lysing fibrin [34].
The clustering of the enzyme optimizes the pattern of
cleavage, but it has some negative impact on the kinetics
of enzyme action. The macroscopic consequence of plas-
min clustering was found to be a gradual decay of its
lytic efficiency, which was quantitatively expressed in
fractal kinetic terms as a time-dependent increase of the
Michaelis constant (KFm) of plasmin [34]. A further obser-
vation was that low concentrations of the lysine analogue
aminohexanoic acid can promote plasmin digestion of




There is a link between fibrin structure and risk of cardio-
vascular events [7]. Many studies (e.g. [36]) evidence that
thin fibers (formed at high thrombin concentrations for
example [37]) are more difficult to dissolve on a macro-
scopic scale than thick fibers, despite the faster digestion
of individual thin fibers. This apparent contradiction may
be explained by efficient plasmin action on tightly packed
monomers within a single thick cross section, avoiding
slower steps where plasmin must diffuse through the
pores of the network. Many factors other than thrombin
concentration can regulate clot structure [7,38], including
some specific cellular interactions which will be dealt with
below.
Platelet effects on clot structure In vivo, fibrin is formed
at sites of blood vessel injury where platelets are also
activated and bind fibrin. Thus, the strong adhesive
forces between platelets and fibrin, in combination with
platelet contraction, place the fibers under tension that
modulates the clot structure, stiffens fibrin and increases
its density in the platelet-rich areas (‘clot retraction’)
[39]. Similar mechanical stress is exerted on fibrin on the
surface of non-occluding intravascular thrombi exposed
to mechanical shear generated by circulating blood,
which profoundly alters the fibrin architecture: fibers
become longitudinally aligned with a smaller diameter
and pore size compared to the randomly running fibers
in the interior of the same thrombi [40]. Stretching of
in vitro fibrin clots can be used to model the structural
consequences of platelet- and shear-related mechanical
forces. Electron microscopic and small angle X-ray scat-
tering observations evidence that mechanical stress
causes unfolding of the coiled coil region in the fibrin
monomers and exposure of hydrophobic residues [41].
Consequently, fluid is expelled from the vacant space
among the protofibrils within the fibers resulting in a
decrease in fiber diameter and an increase in the protein
density of the fibers. Although unfolding generally ren-
ders proteins more susceptible to enzymatic degradation,
the mechanically stressed fibrin is more resistant to plas-
min digestion [40].
Proteolytic resistance conferred to fibrin by chemical
modifications can also be explained by similar changes in
clot morphology. Factor XIIIa (FXIIIa) is a transgluta-
minase of plasma or platelet origin, known to introduce
c-glutamyl-lysine cross-links between cC- and aC-
domains of adjacent fibrin monomers (reviewed in [42]).
This covalent cross-linking results in a significant reduc-
tion (by about 20%) of the fiber diameter without any
change in the number of protofibrils in a fiber, implying
that FXIIIa tightens the lateral attachment of protofibrils
and decreases the volume of the vacant fluid space within
the fibers [37], accompanied by a two-fold reduction of
the pore size as assessed from clot permeability measure-
ments [43]. Fibrinogen variants have been used to dissect
the roles of a- and c-crosslinks, and a-crosslinking of
fibrin fibers was found to affect appearance, biophysical
properties and delay fibrinolysis [44]. Platelets are also a
source of polyphosphate, which when released from acti-
vated platelets results in localized changes in fibrin struc-
ture. Polyphosphate of sufficient length has been found to
result in thicker fibrin strands that were more resistant to
fibrinolysis [45].
In a plasma environment, additional factors appear to
take a leading role as a determinant of the lytic resistance
conferred by FXIIIa. a2-PI can serve as a substrate of
FXIIIa, and its covalent attachment to fibrin appears to
be indispensable for the lytic stabilization of plasma clots
[46]. Depletion of a2-PI eliminates the antifibrinolytic
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effect of FXIIIa, and lysis rates are inversely correlated
with the amount of a2-PI cross-linked to fibrin in plasma
clots. The antifibrinolytic effect of platelet FXIIIa is also
dependent on the availability of a2-PI [47]. Further
insights into conflicting results concerning the mechanism
of clot stabilization by FXIII—directly altering fibrin
structure and the requirement of a2-PI—may require close
evaluation of experimental methods, including the role of
plasma proteins, platelets and flow.
Red blood cells Although the size of pores between
fibrin fibers (typically 160–380 nm in diameter) allows
free diffusion of macromolecules, if fibrin is formed in
blood, then the entrapped cells cause a significant
reduction in molecular diffusion coefficients [48]. This
pore-filling effect alone could further impair plasmin
diffusion, a rate defining feature discussed above, but
the most abundant blood cells, the erythrocytes, are
more than simply inert bystanders in the clot. They are
involved in active interactions with fibrin through an
integrin receptor [49], and their retention in the clot
requires FXIIIa [50]. Thus, fibrin can transmit the con-
tractile force of neighboring activated platelets to red
blood cells causing a change of their shape from bicon-
cave to polyhedral [51], resulting in almost gap-free
compaction of red blood cells in the vacant space
between fibrin fibers and forming a structure with a
stronger diffusion barrier and higher lytic resistance [52].
Red blood cells entrapped in thrombi express phosphati-
dylserine on their surface [53], which supports the
assembly of prothrombinase complex and accelerates
thrombin generation [54], and at higher thrombin con-
centrations, a fibrin structure with higher lytic resistance
is formed. Increasing the fractional volume of fibrin
occupied by red blood cells from 0 to a physiologically
relevant hematocrit value of 0.4 causes a reduction of
the median fiber diameter from 150 to 96 nm [52]. As
discussed above in relation to mechanical and enzymo-
logical factors, such alterations of fibrin structure result
in lytic resistance. The antifibrinolytic effects of red
blood cells could be reversed by an integrin antagonist,
eptifibatide, suggesting a therapeutic approach to throm-
bosis through the pharmacological blockade of the red
blood cell–fibrin interactions [52].
Neutrophils Neutrophils have been identified as having
a role in fibrinolysis. DNA and histones are components
of ‘neutrophil extracellular traps’ (NETs) released by acti-
vated neutrophils at sites of infection and in intravascular
thrombi (reviewed in [55]), and the effects of NET com-
ponents on fibrinolysis have been summarized [56].
Briefly, histones alone or in complex with DNA result in
thicker fibrin fibers and more robust clots (as shown in
rheology studies), whereas DNA alone causes the oppo-
site effects. Combinations of DNA and histones were
found to have a major effect on clot lysis by being able
to hold lysing fibrin together to delay fibrinolysis. Isother-
mal titration calorimetry studies showed that large FDP
strongly bound to histones and high molecular weight
DNA, which could stabilize lysing clots, results that pro-
vide a rationale for the use of DNase as an adjunct to
thrombolytic therapy [56]. Overall, the conclusions from
these studies are that DNA and histones may strengthen
clots and delay their complete dissolution.
Models of fibrinolysis
A number of groups have attempted to model blood
coagulation (or study ‘blood systems biology’ [57]). Mul-
tiscale models of coagulation that include multiple reac-
tions, flow, concentration gradients and platelets have
been developed with some success, but models of fibrino-
lysis have lagged behind, for number of reasons. An
issue with some fibrinolysis models was the approxima-
tion that fibrin was distributed homogenously rather
than in fibers, which does not permit any investigation
of the effects of fibrin architecture. Bannish et al. [58]
approached this problem by developing a one-dimen-
sional reaction-diffusion model that included a concen-
tration of fibrin that was fixed but heterogeneously
distributed into fiber patterns. As the lysis front travelled
through the clot, the model was able to replicate some
features seen in in vitro clot lysis experiments, including
concentration of tPA and plasminogen at the lysis front
(reported to be up to 30-fold increased for plasminogen
in aggregates in the 3 lm lysis front [11]). However, the
authors concluded the model was not entirely satisfac-
tory and suggested that low concentrations of circulating
tPA, amounting to three molecules per lm3, argued in
favor of a stochastic approach. Their 3D stochastic mul-
tiscale model [59] followed a number of tPA molecules
binding to fibrin and activating bound plasminogen lead-
ing to transverse cutting of fibrin fibers, rather than uni-
form degradation that limited the earlier model. Detailed
biochemical considerations, including binding and
unbinding terms and uncovering of cryptic sites (C-ter-
minal lysines), were included to develop the first stage
microscale stochastic model, providing results for a sub-
sequent macroscale stage to simulate transport of reac-
tants and large-scale fibrin clot lysis. Very recently, we
have validated the 3D stochastic model over ranges of
tPA and plasminogen concentrations in clot lysis experi-
ments using standardized clots fully characterized by
scanning electron microscopy, with good results [60].
Future work will allow hypotheses to be tested and gen-
erated to better understand the regulation of fibrinolysis
by the activators and inhibitors discussed above, and
explore the significance of fibrin architecture, flow and
cellular interactions.
This review has touched on the basic principles of fibri-
nolysis and highlighted current knowledge on important
regulatory features. Improved understanding of regulation
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may lead to advances in thrombolytic therapy, which is
still widely practiced, for stroke and myocardial infarc-
tion. Infectious diseases are also major sources of human
mortality and morbidity and involve interactions with
host fibrinolysis pathways that provide targets for thera-
peutic interventions. Considering the range of physiologi-
cal processes that involve fibrinolysis reactions, greater
knowledge of the regulation of this system has significant
potential for improving human health.
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